Xvivo Perfusion AB

As of June 30, 2026, Xvivo Perfusion AB carries a market capitalization of 8.18B, placing it among publicly traded companies globally. Its enterprise value stands at 7.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Xvivo Perfusion AB's next confirmed earnings release is scheduled for January 28, 2027.

As of June 30, 2026, Xvivo Perfusion AB has 31.50M shares outstanding.

As of June 30, 2026, Xvivo Perfusion AB trades at a trailing price-to-earnings ratio of 95.30. The price-to-sales ratio is 9.25, and the price-to-book ratio stands at 3.72.

As of June 30, 2026, Xvivo Perfusion AB trades at an EV/EBITDA multiple of 79.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 79.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Xvivo Perfusion AB trades at an EV/FCF ratio of 35.60, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.99B versus a market cap of 8.18B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Xvivo Perfusion AB maintains a current ratio of 3.86, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Xvivo Perfusion AB posted a return on equity (ROE) of 4.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.43 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.56, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.86, useful for judging operating efficiency across full business cycles. The company generates approximately 4.37M in revenue per employee across its workforce of 202.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.09 indicates how many times Xvivo Perfusion AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Xvivo Perfusion AB recorded 27.60M in income tax expense. That works out to an effective tax rate of 24.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 113.41M, leaving 85.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Xvivo Perfusion AB's stock has gained approximately 24.46% over the past 52 weeks. The 50-day moving average sits at 246.83, while the 200-day moving average is 243.97.

Over the twelve months ended June 30, 2026, Xvivo Perfusion AB generated 884.39M in revenue and converted that into 85.80M in net income, yielding earnings per share of 2.72. EBITDA reached 100.84M, while operating income came in at 100.84M.

As of June 30, 2026, Xvivo Perfusion AB holds 304.97M in cash and equivalents against 121.62M in total debt, resulting in a net debt position of -304.96M. Total book value stands at 2.20B, with working capital of 540.02M providing operational flexibility.

Xvivo Perfusion AB produced 224.56M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Xvivo Perfusion AB posted a gross margin of 72.06, reflecting its pricing power and cost economics. The operating margin of 11.40 and net profit margin of 9.70 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.74, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.89, meaning Xvivo Perfusion AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Xvivo Perfusion AB has an Altman Z-Score of 17.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.